Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma

By Koh Y.   Lim H. Y.   Ahn J. H.   Lee J.-L.   Rha S. Y.   Kim Y. J.   Kim T. M.   Lee S.-H.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1026-1031

Oxford University Press

Access to resources Recommend Favorite

Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma

By Kim Ki   Yoon Sang   Lee Hae-Jung   Kim Hyo   Shin Sang   Ahn Joong   Rha Sun  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 4, 2013-10 ,pp. : 853-860

Springer Publishing Company

Access to resources Recommend Favorite

Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study

By Shinsako Keiko   Mizuno Tomoyuki   Terada Tomohiro   Watanabe Jun   Kamba Tomomi   Nakamura Eijiro   Ogawa Osamu   Inui Ken-ichi  

International Journal of Clinical Oncology, Vol. 15, Iss. 5, 2010-10 ,pp. : 512-514

Springer Publishing Company

Access to resources Recommend Favorite

Sorafenib and Everolimus in Advanced Clear Cell Renal Carcinoma: A Phase I/II Trial of the SCRI Oncology Research Consortium

By Hainsworth John D.   Waterhouse David M.   Penley William C.   Shipley Dianna L.   Thompson Dana S.   Webb Charles D.   Anthony Greco F.  

Cancer Investigation, Vol. 31, Iss. 5, 2013-06 ,pp. : 323-329

Informa Healthcare

Access to resources Recommend Favorite

Anti-Angiogenic Therapy in Renal Cell Carcinoma

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 5, Iss. 1, 2010-01 ,pp. : 77-83

Bentham Science Publishers

Access to resources Recommend Favorite